Medcolcanna Organics Inc. and Grupo Curativa SAS Enter Into a Joint Venture Agreement for the Development and Commercialization of Cannabis Based Pharmaceutical ProductsPosted by On


/EIN News/ — BOGOTÁ, Colombia, Sept. 10, 2020 (GLOBE NEWSWIRE) — Medcolcanna Organics Inc. (TSXV: MCCN), through its wholly-owned subsidiary Medcolcanna SAS (“Medcolcanna”, “MCCN” or the “Company”), a leading Colombian integrated cannabis company, is pleased to announce that it has entered into a joint venture agreement for the development and commercialization of cannabis based pharmaceutical products with Grupo Curativa SAS (“Curativa”), an interdisciplinary group of physicians and scientists, internationally recognized for their development and commercialization of various carefully researched products with varying ratios of THC, CBD and other cannabinoids across human and veterinary populations. These formulas have been tested for numerous clinical conditions in over 4,000 patients over the past six years in Colombia, as well as internationally.

MCCN’s proprietary formulations are expected to be distributed…

Original Author Link click here to read complete story..

News

AgreementbasedcannabisCommercializationCurativaDevelopmententerGrupojointMedcolcannaOrganicsPharmaceuticalproductsSAsventure

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.